Early Development Programs
Tavanta is exploring several early development programs, including new chemical entities, in multiple sclerosis, cystic fibrosis, autoimmune disorders, and other therapeutic areas.
TAVT-124 is a small molecule being explored as a treatment for multiple sclerosis and autoimmune disorders with a novel mechanism of action. In preclinical disease models, TAVT-124 demonstrated improved measures of disability compared with an approved disease modifying therapy.
TAVT-135 is an inhaled peptide-small molecule conjugate being explored as a treatment for cystic fibrosis. TAVT-135 has a unique mechanism of action for restoring chloride ion transport across cell membranes.